Ionis Pharmaceuticals, Inc. Convertible Debt, Current
Ionis Pharmaceuticals, Inc. (IONS) had Convertible Debt, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:ConvertibleDebtCurrent · last filed 2026-07-29
- 2026-06-30: Convertible Debt, Current $0.00.
- 2026-03-31: Convertible Debt, Current $432.50M.
- 2025-12-31: Convertible Debt, Current $431.95M.
- 2025-09-30: Convertible Debt, Current $630.91M.
| Period end | Convertible Debt, Current | Convertible Debt, Current as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $432.50M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $431.95M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $630.91M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $630.12M 10-Q · filed 2025-07-30 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $44.47M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $44.42M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $44.38M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $44.33M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-21 | |
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 | |
| 2021-09-30 | $61.94M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $61.88M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $61.82M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $308.81M 10-K · filed 2022-02-25 | $293.16M 10-K · filed 2021-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |